OrganOx raises £25m in a growth round led by Lauxera Capital Partners to scale commercial operations.
The Oxford-based medical technology company secured backing from Lauxera Capital Partners to expand its US footprint and advance research pipelines.
OrganOx is a medical technology company that develops automated normothermic machine perfusion devices for liver transplantation. Its flagship product, metra, preserves donor livers and allows surgeons to assess function prior to transplant.
OrganOx has secured £25m in a growth round led by Lauxera Capital Partners, with participation from existing backers. The capital will be deployed to scale the commercial presence of the business, particularly by expanding customer-facing operations in the US market.
Additional funds will be directed towards new infrastructure in the UK and US to accelerate research and development pipelines targeting adjacent markets in organ transplantation. The company has seen rapid adoption of its metra device across Europe, the US and Australia, with more than 2,500 successful liver transplants supported to date.
From the founder
"We are thrilled to have Lauxera Capital Partners at the table. Their collective experiences will be invaluable to OrganOx as we execute our commercial strategy in Europe, North America and Australia. OrganOx is committed to using our NMP technology to make organs more widely available to patients who need them around the world."
Craig Marshall
Chief Executive Officer at OrganOx
Investor perspective
"Lauxera is proud and honoured to back the OrganOx team and its global commercial scale-up. This is the ninth investment made by Lauxera Growth I, a growth buy-out fund dedicated to investing in commercial-stage European and North American HealthTech businesses."
Sam Levy
MD, Lauxera Capital Partners
Use of funds
- 01Expand into international markets
- 02Build out infrastructure
- 03Fund research and development
